Results 181 to 190 of about 602,267 (275)

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang   +4 more
wiley   +1 more source

Infections and their determinants in patients with non‐Hodgkin lymphoma receiving bispecific T‐cell antibodies: Results from an international multicenter cohort study

open access: yes
HemaSphere, Volume 10, Issue 11, November 2026.
Zainab Shahid   +17 more
wiley   +1 more source

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ‐B3101) in Pediatric Patients With Relapsed/Refractory Anaplastic Lymphoma Kinase‐Positive Anaplastic Large‐Cell Lymphoma: A Phase I Study

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This Phase I study evaluated unecritinib (TQ‐B3101) in pediatric patients with relapsed/refractory ALK+ anaplastic large‐cell lymphoma. Unecritinib showed a manageable safety profile without dose‐limiting toxicities and achieved remarkable efficacy, with a 100% overall response rate.
Suying Lu   +10 more
wiley   +1 more source

Progenitor cell self-renewal and cyclic neutropenia. [PDF]

open access: yesCell Prolif, 2009
Dingli D   +3 more
europepmc   +1 more source

Fruquintinib Plus FOLFIRI/FOLFOX as Second‐Line Therapy in Patients With RAS‐Mutant Metastatic Colorectal Cancer: A Multicenter, Open‐Label, Single‐Arm Phase II Study

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This phase II trial demonstrates that fruquintinib combined with chemotherapy achieves a median progression‐free survival of 8.08 months and a 52.5% objective response rate as second‐line therapy for RAS‐mutant metastatic colorectal cancer, with a notable 7.14% conversion surgery rate.
Yun Xu   +9 more
wiley   +1 more source

Clozapine‐Associated Neutropenia With COVID‐19 Infection and the Role of Filgrastim

open access: yesProgress in Neurology and Psychiatry, Volume 30, Issue 4, November 2026.
ABSTRACT Clozapine is the gold standard, evidence‐based treatment of choice for treatment‐resistant schizophrenia. However, clozapine can induce serious, life‐threatening adverse effects, including neutropenia and agranulocytosis. There is accumulating evidence to suggest that rechallenging with clozapine should be considered in most patients with ...
Devender Singh Yadav
wiley   +1 more source

Home - About - Disclaimer - Privacy